A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patients.

Objectives: To assess the efficacy and safety of an intra-articular (IA) CLK/DYRK inhibitor, lorecivivint (LOR), for the treatment of moderate to severe symptomatic knee osteoarthritis (OA).

Methods: This was a Phase 3, 28-week, multicentre, double-blind, placebo-controlled study evaluating the efficacy and safety of a single IA injection of LOR. Patients with ACR-defined knee OA, Kellgren-Lawrence (KL) grades 2-3, and pain Numeric Rating Scale (NRS) ≥4 and ≤8 in the target knee were randomised (1:1) to receive LOR 0.

Phase 3, 56-week, randomised, double-blind, placebo-controlled study utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis: OA-11 Study.

Objectives: To determine the efficacy, safety, and tolerability of intraarticular (IA) lorecivivint (LOR) in the treatment of knee osteoarthritis (OA).

Methods: Patients with American College of Rheumatology criteria-defined knee OA, Kellgren-Lawrence (KL) grades 2-3, and medial Joint Space Width (JSW) by radiograph between 1.5 and 4 mm in the target knee were enrolled in this phase 3, 56-week, multicentre, double-blind, placebo-controlled study.

Exploring the frontiers of metal additive manufacturing in orthopaedic implant development.

This paper provides a thorough analysis of recent advancements and emerging trends in the integration of metal additive manufacturing (AM) within orthopedic implant development. With an emphasis on the use of various metals and alloys, including titanium, cobalt-chromium, and nickel-titanium, the review looks at their characteristics and how they relate to the creation of various orthopedic implants, such as spinal implants, hip and knee replacements, and cranial-facial reconstructions. The study highlights how metal additive manufacturing (AM) can revolutionize the field by enabling customized implant designs that take patient anatomical variances into account.

Ocular examinations before and after total ear canal ablation and bulla osteotomy can help recognize and prevent potential vision-threatening abnormalities in cats and dogs.

Objective: To report ocular examination findings before and after total ear canal ablation and lateral bulla osteotomy (TECALBO) and ventral bulla osteotomy (VBO) in cats and dogs.

Methods: At The Ohio State University and MedVet Columbus, ophthalmic examinations were performed on client-owned animals for which a TECALBO or VBO was indicated. Examination findings and postoperative complications relating to ophthalmic and/or neuro-ophthalmic diseases were recorded prior to surgery (T0) and at 1 day (T1), 2 to 3 weeks (T14), and ± 2 months (T60) postoperatively.

Evaluation of Safety and Efficacy of a Single Lorecivivint Injection in Patients with Knee Osteoarthritis: A Multicenter, Observational Extension Trial.

Introduction: Lorecivivint (LOR), a CDC-like kinase/dual-specificity tyrosine kinase (CLK/DYRK) inhibitor thought to modulate inflammatory and Wnt pathways, is being developed as a potential intra-articular knee osteoarthritis (OA) treatment. The objective of this trial was to evaluate long-term safety of LOR within an observational extension of two phase 2 trials.

Methods: This 60-month, observational extension study (NCT02951026) of a 12-month phase 2a trial (NCT02536833) and 6-month phase 2b trial (NCT03122860) was administratively closed after 36 months as data inferences became limited.